Skip to main content

Table 1 Demographics and baseline characteristics

From: The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

 

BLyS mRNA low

BLyS mRNA medium

BLyS mRNA high

IFN-1 mRNA low

IFN-1 mRNA high

Revised BLyS mRNA low

Revised BLyS mRNA high

BLyS protein* low

BLyS protein* high

PBO

BEL

PBO

BEL

PBO

BEL

PBO

BEL

PBO

BEL

PBO

BEL

PBO

BEL

PBO

BEL

PBO

BEL

n = 85

n = 99

n = 104

n = 81

n = 84

n = 101

n = 43

n = 49

n = 230

n = 232

n = 93

n = 111

n = 180

n = 170

n = 208

n = 220

n = 64

n = 61

Age, years, mean (SD)

39.2 (13.17)

38.8 (11.06)

36.5 (12.12)

36.8 (11.34)

37.6 (10.70)

37.0 (11.29)

43.3 (13.66)

42.5 (11.27)

36.6 (11.47)

36.5 (10.95)

38.9 (13.35)

38.5 (10.69)

37.0 (11.32)

36.9 (11.54)

38.0 (12.27)

38.4 (11.41)

36.3 (11.26)

34.4 (9.99)

Female, n (%)

79 (92.9)

96 (97.0)

95 (91.3)

81 (100.0)

78 (92.9)

97 (96.0)

39 (90.7)

47 (95.9)

213 (92.6)

227 (97.8)

86 (92.5)

108 (97.3)

166 (92.2)

166 (97.6)

197 (94.7)

213 (96.8)

54 (84.4)

61 (100.0)

SLE disease duration, years, mean (SD)

6.0 (6.23)

5.8 (7.30)

6.4 (6.41)

6.9 (6.54)

7.7 (6.35)

6.3 (5.99)

6.0 (6.52)

4.8 (5.99)

6.8 (6.32)

6.6 (6.72)

6.1 (6.07)

5.8 (7.12)

7.0 (6.48)

6.7 (6.28)

6.3 (6.09)

6.0 (6.38)

8.1 (7.03)

7.3 (7.41)

BILAG organ domain involvement, n (%)

 ≥ 1A or 2B

54 (63.5)

47 (47.5)

63 (60.6)

48 (59.3)

56 (66.7)

57 (56.4)

28 (65.1)

24 (49.0)

145 (63.0)

128 (55.2)

60 (64.5)

56 (50.5)

113 (62.8)

96 (56.5)

126 (60.6)

112 (50.9)

47 (73.4)

40 (65.6)

 ≥ 1A

8 (9.4)

3 (3.0)

10 (9.6)

12 (14.8)

13 (15.5)

9 (8.9)

6 (14.0)

1 (2.0)

25 (10.9)

23 (9.9)

8 (8.6)

3 (2.7)

23 (12.8)

21 (12.4)

25 (12.0)

18 (8.2)

6 (9.4)

6 (9.8)

 ≥ 1A or 1B

80 (94.1)

84 (84.8)

94 (90.4)

72 (88.9)

76 (90.5)

89 (88.1)

41 (95.3)

43 (87.8)

209 (90.9)

202 (87.1)

86 (92.5)

96 (86.5)

164 (91.1)

149 (87.6)

191 (91.8)

187 (85.0)

58 (90.6)

58 (95.1)

 No A or B

5 (5.9)

15 (15.2)

10 (9.6)

9 (11.1)

8 (9.5)

12 (11.9)

2 (4.7)

6 (12.2)

21 (9.1)

30 (12.9)

7 (7.5)

15 (13.5)

16 (8.9)

21 (12.4)

17 (8.2)

33 (15.0)

6 (9.4)

3 (4.9)

SELENA-SLEDAI category, n (%)

 ≤ 9

55 (64.7)

56 (56.6)

51 (49.0)

35 (43.2)

35 (41.7)

48 (47.5)

27 (62.8)

33 (67.3)

114 (49.6)

106 (45.7)

57 (61.3)

59 (53.2)

84 (46.7)

80 (47.1)

117 (56.3)

118 (53.6)

24 (37.5)

21 (34.4)

 10–11

19 (22.4)

20 (20.2)

27 (26.0)

20 (24.7)

19 (22.6)

22 (21.8)

9 (20.9)

9 (18.4)

56 (24.3)

53 (22.8)

22 (23.7)

23 (20.7)

43 (23.9)

39 (22.9)

47 (22.6)

46 (20.9)

17 (26.6)

16 (26.2)

 ≥ 12

11 (12.9)

23 (23.2)

26 (25.0)

26 (32.1)

30 (35.7)

31 (30.7)

7 (16.3)

7 (14.3)

60 (26.1)

73 (31.5)

14 (15.1)

29 (26.1)

53 (29.4)

51 (30.0)

44 (21.2)

56 (25.5)

23 (35.9)

24 (39.3)

SELENA-SLEDAI score, mean (SD)

8.6 (2.43)

9.2 (3.74)

9.4 (3.87)

9.6 (3.50)

10.4 (4.57)

9.7 (3.56)

8.6 (2.91)

8.5 (3.65)

9.6 (3.92)

9.7 (3.56)

8.8 (2.73)

9.3 (3.64)

9.8 (4.21)

9.6 (3.59)

8.9 (3.21)

9.2 (3.59)

11.0 (4.98)

10.5 (3.48)

Anti-dsDNA (≥ 30 IU/mL), n (%)

42 (49.4)

57 (57.6)

75 (72.1)

58 (71.6)

61 (72.6)

82 (81.2)

17 (39.5)

18 (36.7)

161 (70.0)

179 (77.2)

49 (52.7)

65 (58.6)

129 (71.7)

132 (77.6)

126 (60.6)

145 (65.9)

51 (79.7)

52 (85.2)

Low C3 and/or low C4, n (%)

39 (45.9)

62 (62.6)

71 (68.3)

52 (64.2)

61 (72.6)

75 (74.3)

12 (27.9)

21 (42.9)

159 (69.1)

168 (72.4)

44 (47.3)

69 (62.2)

127 (70.6)

120 (70.6)

121 (58.2)

137 (62.3)

49 (76.6)

52 (85.2)

Anti-dsDNA (≥ 30 IU/mL) and low C3 and/or low C4), n (%)

26 (30.6)

44 (44.4)

60 (57.7)

43 (53.1)

52 (61.9)

70 (69.3)

8 (18.6)

10 (20.4)

130 (56.5)

147 (63.4)

31 (33.3)

48 (43.2)

107 (59.4)

109 (64.1)

97 (46.6)

110 (50.0)

40 (62.5)

47 (77.0)

  1. *One patient was excluded as he/she did not have a baseline BLyS protein assessment
  2. BEL belimumab, BILAG British Isles Lupus Assessment Group of SLE Clinics, BLyS B lymphocyte stimulator, IFN interferon, IFN-1 type 1 IFN-inducible gene signature, mRNA messenger ribonucleic acid, PBO placebo, SD standard deviation, SELENA-SLEDAI Safety of Estrogen in Lupus Erythematosus National Assessment trial-Systemic Lupus Erythematosus Disease Activity Index, SLE systemic lupus erythematosus